NCT03120702

Brief Summary

Assess ability of Masimo SpHb sensor to demonstrate robust performance on various sensor application sites on neonates/infants

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
128

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 23, 2013

Completed
3.7 years until next milestone

First Submitted

Initial submission to the registry

April 14, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 19, 2017

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 20, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 20, 2017

Completed
Last Updated

April 28, 2021

Status Verified

April 1, 2021

Enrollment Period

3.7 years

First QC Date

April 14, 2017

Last Update Submit

April 26, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assess ability of Masimo SpHb sensor to demonstrate robust performance on various sensor application sites on neonates/infants

    To study the SpHb sensor in neonatal population.

    duration of surgery

Study Arms (1)

Neonatal Test Subjects

EXPERIMENTAL

All test subjects in this group are neonatal patients who will receive a investigational Rainbow SpHb sensor.

Device: Investigational Rainbow SpHb sensor

Interventions

Investigational Rainbow SpHb sensor

Neonatal Test Subjects

Eligibility Criteria

AgeUp to 16 Weeks
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Male or female newborn infants of any gestational age requiring at least one (1) blood draw as part of their routine care.
  • Ages: Newborn infants less than 16 weeks postnatal age.
  • Weight: Range from 500 g to 10 kg.
  • Able to obtain written informed consent from parents or legal guardians

You may not qualify if:

  • Neonatal patients with abnormalities at the planned application sites that would interfere with transilluminating the foot or hand like unusual deformities of limbs, absence of feet, severe edema, localized infections, and other.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital of Orange County

Orange, California, 92868, United States

Location

MeSH Terms

Conditions

Anemia

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2017

First Posted

April 19, 2017

Study Start

July 23, 2013

Primary Completion

April 20, 2017

Study Completion

April 20, 2017

Last Updated

April 28, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

Locations